## MTD: Mettler-Toledo International, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -6.3% below STRENGTH zone (4.0-10.0%); PEG 3.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1298.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Amundi Sells 9,062 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251208T170848 | Neutral | Relevance: 99%
-  Amundi has reduced its stake in Mettler-Toledo International, Inc. by 7.5%, selling 9,062 shares and now holding 111,247 shares valued at approximately $134.13 million. Recent insider transactions show significant selling by company executives, totaling $28.68 million in the past three months. Analysts currently have a "Hold" consensus rating on the stock with a price target of $1,419.55, though some have recently raised their targets.

**2. Mettler-Toledo Stock: Is MTD Underperforming the Healthcare Sector?**
- Source: inkl | 20251208T120819 | Somewhat-Bullish | Relevance: 98%
-  Mettler-Toledo International Inc. (MTD) is a leader in precision instruments with a market cap of $28.9 billion. While MTD shares have underperformed the Health Care Select Sector SPDR Fund (XLV) in the last three months, they have outpaced XLV year-to-date and over the past 52 weeks. Despite recent fluctuations and a slight dip after better-than-expected Q3 earnings, analysts maintain a "Moderate Buy" rating for MTD, suggesting a 7% upside.

**3. Mettler-Toledo International Stock Slides 8.3% With A 8-Day Losing Spree**
- Source: Trefis | 20251209T080829 | Neutral | Relevance: 98%
- Mettler-Toledo International stock has seen an 8.3% decline, marking an eight-day losing streak. The article provides this key financial information regarding the company's recent stock performance.

**4. Goldman Sachs Initiates Coverage on Mettler-Toledo (MTD) with Ne**
- Source: GuruFocus | 20251209T140824 | Somewhat-Bullish | Relevance: 97%
-  Goldman Sachs has initiated coverage on Mettler-Toledo International Inc. (MTD) with a 'Neutral' rating and a price target of $1,475.00 USD. This report highlights recent analyst activities and forecasts for MTD, noting an average target price of $1,490.41 from 13 analysts, suggesting an upside of 7.89% from its current price. Mettler-Toledo specializes in weighing and precision instruments for life sciences, industrial, and food retail sectors.

**5. The Goldman Sachs Group Begins Coverage on Mettler-Toledo International (NYSE:MTD)**
- Source: MarketBeat | 20251209T133331 | Neutral | Relevance: 97%
-  The Goldman Sachs Group initiated coverage on Mettler-Toledo International (NYSE:MTD) with a "neutral" rating and a $1,475.00 price target, suggesting a potential upside of 6.69% from its current trading price. This new coverage joins other recent analyst reports, resulting in a consensus "Hold" rating and an average target price of $1,424.17 for the medical instruments supplier. Mettler-Toledo International recently reported strong quarterly earnings, beating analyst expectations, and several institutional investors have adjusted their stakes in the company.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $1475 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |
| 2025-11-10 | Citigroup | $1700 | $1600 | +6% |
| 2025-11-10 | Barclays | $1600 | $1350 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-10 | Citigroup | main | Buy |
| 2025-11-10 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.64 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Analyst sentiment positive (4 raises, avg +13%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $28.2B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.64 |
| Forward P/E | 30.0 |
| Current P/E | 32.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.2% to -6.3% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.3pp (needs >4.0% for momentum thesis). AM_20 at -4.2% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-12.47), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.26% (CS: 9) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -12.47 | Bearish |
| vs SMA20 | 0.958x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1371.42
- **Stop Loss:** $1298.12 (5.3% risk)
- **Target:** $1444.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 4
- **Position Value:** $5,485.68
- **Portfolio %:** 5.49%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*